Pluristem Life Systems, Inc. (OTCBB: PLRS) is a biotechnology Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company’s first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained umbilical cord blood (CB).
Pluristem’s products are derived from Mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company’s proprietary PluriX™ 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.
MATAM Advanced Technology Park
# 20
Haifa 31905, Israel
Tel: 972-4-850-1080
Fax: 972-4-850-1085
E-Mail:info@pluristem.com
